Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Jones T. Nauseef,Paul J. Christos,Charlene Thomas,Luke T. Nordquist,Cora N. Sternberg,Himisha Beltran,Sabrina Guervil,Giuseppe Galletti,Paraskevi Giannakakou,David M. Nanus,Scott T. Tagawa,Ana M. Molina

Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).

2021

Jones T. Nauseef
Paul J. Christos
Charlene Thomas
Luke T. Nordquist
Cora N. Sternberg
Himisha Beltran
Sabrina Guervil
Giuseppe Galletti
Paraskevi Giannakakou
David M. Nanus
Scott T. Tagawa
Ana M. Molina

140Background: The combination of AR inhibition plus taxane chemotherapy has demonstrated clinical benefit in PC (i.e. CHAARTED, STAMPEDE), indicating efficacy when targeting the AR signaling pathw...

Keywords:

Prostate cancer
Prednisone
Apalutamide
Oncology
Abiraterone acetate
Docetaxel
castration resistant
Medicine
Taxane
Internal medicine
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations